Results 191 to 200 of about 1,768,776 (397)

Variability in the reported management of pulmonary metastases in osteosarcoma. [PDF]

open access: yes, 2015
Nearly 20% of patients with newly diagnosed osteosarcoma have detectable metastases at diagnosis; the majority of which occur in the lungs. There are no established recommendations for the timing and modality of metastasectomy.
Bhattasali, Onita   +6 more
core  

Rewiring Neuroimmunity: Nanoplatform Innovations for CNS Disease Therapy

open access: yesAdvanced Therapeutics, EarlyView.
This review explores emerging nanoplatform strategies designed to modulate neuroimmune responses for treating central nervous system (CNS) disorders. It examines structural and microenvironmental barriers, advances in multifunctional and targeted nanotechnologies, and highlights clinical progress and translational challenges, offering insights into the
Muhammad Usman Akbar   +7 more
wiley   +1 more source

Nomograms to predict long‐term survival for patients with gallbladder carcinoma after resection

open access: yesCancer Reports
Background Surgical resection remains the primary treatment option for gallbladder carcinoma (GBC). However, there is a pressing demand for prognostic tools that can refine patients' treatment choices and tailor personalized therapies accordingly.
Shilei Bai   +8 more
doaj   +1 more source

Anisotropic Surface Microrollers for Endovascular Navigation: A Computational Analysis with a Case Study in Hepatic Perfusion

open access: yesAdvanced Theory and Simulations, EarlyView.
Computational fluid dynamics analyses assess the upstream locomotion performance of anisotropic microrollers with varying height‐to‐width ratios. Observing their successful upstream locomotion in veins, their performance in hepatic circulation is investigated for treating primary liver cancer.
Burak Arslan   +8 more
wiley   +1 more source

SMYD3 Promotes Immune Evasion in Clear Cell Renal Cell Carcinoma via SREBP1‐Mediated Transactivation of CD47

open access: yesAdvanced Science, EarlyView.
Cancer cell‐intrinsic SMYD3 orchestrates an immunosuppressive microenvironment and impairs the response to PD‐1 blockade by reprogramming immune cells landscape in the tumor microenvironment of clear cell renal cell carcinoma (ccRCC). The immunomodulatory function of SMYD3 is mediated via the SREBP1/CD47 pathway.
Zhengfang Liu   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy